- Home
- DXLG vs XFOR Comparison
DXLG vs XFOR Comparison
Compare DXLG & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXLG
- XFOR
- Stock Information
- Founded
- DXLG 1976
- XFOR 2014
- Country
- DXLG United States
- XFOR United States
- Employees
- DXLG N/A
- XFOR N/A
- Industry
- DXLG Clothing/Shoe/Accessory Stores
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DXLG Consumer Discretionary
- XFOR Health Care
- Exchange
- DXLG Nasdaq
- XFOR Nasdaq
- Market Cap
- DXLG 128.2M
- XFOR 118.4M
- IPO Year
- DXLG 1987
- XFOR N/A
- Fundamental
- Price
- DXLG $0.99
- XFOR $3.21
- Analyst Decision
- DXLG Buy
- XFOR Strong Buy
- Analyst Count
- DXLG 2
- XFOR 3
- Target Price
- DXLG $2.75
- XFOR $72.33
- AVG Volume (30 Days)
- DXLG 303.4K
- XFOR 138.5K
- Earning Date
- DXLG 05-29-2025
- XFOR 05-01-2025
- Dividend Yield
- DXLG N/A
- XFOR N/A
- EPS Growth
- DXLG N/A
- XFOR N/A
- EPS
- DXLG 0.05
- XFOR 2.16
- Revenue
- DXLG $467,015,000.00
- XFOR $31,364,000.00
- Revenue This Year
- DXLG N/A
- XFOR $355.69
- Revenue Next Year
- DXLG $3.44
- XFOR $140.28
- P/E Ratio
- DXLG $20.20
- XFOR $1.52
- Revenue Growth
- DXLG N/A
- XFOR N/A
- 52 Week Low
- DXLG $0.90
- XFOR $3.05
- 52 Week High
- DXLG $3.93
- XFOR $34.20
- Technical
- Relative Strength Index (RSI)
- DXLG 39.58
- XFOR 22.18
- Support Level
- DXLG $0.93
- XFOR $3.05
- Resistance Level
- DXLG $1.20
- XFOR $3.41
- Average True Range (ATR)
- DXLG 0.09
- XFOR 0.60
- MACD
- DXLG 0.04
- XFOR -0.02
- Stochastic Oscillator
- DXLG 35.00
- XFOR 8.94
About DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.